Company: MDCXW
Filing Date: 2025-05-05
Form Type: 424B3
Source: 0001062993-25-008444
Chunk: 42

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-05
Form: 424B3
Chunk 42
---
 entity; or

(v)the approval by the shareholders of the Company of any plan of liquidation or dissolution of the Company.

If there is a consolidation, merger or statutory amalgamation or arrangement of the Company with or into another corporation, a separation of the business of the Company into two or more entities or a sale, lease exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company to another entity, upon the exercise or settlement, as applicable, of an Award under the Equity Incentive Plan the holder thereof shall be entitled to receive the securities, property or cash which the holder would have received upon such consolidation, merger, amalgamation, arrangement, separation or transfer if the holder had been the holder of Common Shares immediately prior to effective time of such event, unless the Committee otherwise determines appropriate adjustments or substitutions to be made in such circumstances in order to maintain the economic rights of the Participant in respect of such Award in connection with such event.

Non-Assignable

No rights under the Equity Incentive Plan and no Award granted pursuant to the Equity Incentive Plan are assignable or transferable by any Participant other than pursuant to a will or by the laws of descent and distribution.

Securities Authorized for Issuance under The Equity Incentive Plan

The following table sets forth the number of common shares to be issued, including upon exercise of outstanding convertible securities, pursuant to the Company's equity compensation plans, the weighted average exercise price of such outstanding convertible securities and the number of common shares remaining available for future issuance under equity compensation plans as at December 31, 2024.

| Plan Category                                              |         Number of common 
 shares to be issued upon 
  exercise of outstanding 
    Options, warrants and 
                   rights | Weighted-average     
 exercise price of    
 outstanding Options, 
 warrants and rights  |      Number of common 
      shares remaining 
  available for future 
 issuance under equity 
    compensation plans |
| Equity compensation plans approved by security holders     |                1,185,000 | C$2.06               |               801,556 |
| Equity compensation plans not approved by security holders |                        - | -                    |                     - |
| Total                                                      |                1,185,000 | C$2.06               |               801,556 |

<div align='center'>27</div>

Item 13. Certain Relationships and Related Transactions, and Director Independence.
INDEBTEDNESS OF DIRECTORS AND EXECUTIVE